Arrowstreet Capital’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Arrowstreet Capital's NRIX Position: Q3 2026 in Review
Arrowstreet Capital increased its Nurix Therapeutics (NRIX) stake by 168% in Q3 2026, buying an estimated $20M and bringing the position to 1,280,701 shares worth $30.4M. The position accounts for 0.01% of the portfolio, ranked #689.
Arrowstreet Capital first reported a position in NRIX in Q4 2023 and has held it in 5 quarters since. 231 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Arrowstreet Capital held 1,280,701 shares of Nurix Therapeutics worth $30.4M as of Q3 2026.
- Arrowstreet Capital bought 803,560 Nurix Therapeutics shares in Q3 2026, an estimated $20M.
- Nurix Therapeutics made up 0.01% of Arrowstreet Capital's portfolio in Q3 2026, its #689 holding.
- Arrowstreet Capital first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 5 quarters since.
- 231 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.